General information:
Substance group: Anticonvulsant ATC: N03AX09
Trade names: Elmendos®, EspaTrigin®, Lamictal®, Lamo- ®, Lamotrigin- ®
available dosages: chewable tablets / tablets to make a suspension
2 / 5 / 25 / 50 / 100 / 200 mg
Reference ranges: 3 – 14 mg/L
Toxic Plasma levels: 30 mg/L
Pharmacokinetics:
T1⁄2 : 33 h (14 – 103 h depends on co-medication)
Tmax : 2,5 h
Bioavailability: 100%
Protein binding: 55%
Clearance: 30 mL/min
Excretion: urine: > 90%; faeces: 2%
Metabolism: hepatic
Therapeutic width: 1 – 4 mg/L
toxic: 15 mg/L
Distribution volume: 0.92 – 1.22 L/kg
Time to steady state: intraindividual fluctuations
Sampling:
Material: Serum (Monovette brown) Minimum volume for analysis: 500µl
Recommendation: trough level (directly before the next intake)
Requirement (internal): about Orbis requirement (external):
Analytics:
Test principle: liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)
Protein precipitation with acetonitrile, chromatographic separation, mass spectrometry
Analysis according to mass charge ratio
Analysis system: triple stage Quadrupol mass spectrometer (LC-MS/MS)
Findings release: on the same working day, via LIMS
DrugBank: